$PHAT
Phathom Pharmaceuticals, Inc. Stock $phat

$phat Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000156459019044367 Filed on November 25, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.990M	$1.810M	$440.0K
YoY Change	579.55%	596.15%
% of Gross Profit
Research & Development	$12.70M	$4.469M	$14.00K
YoY Change	90642.86%	74383.33%
% of Gross Profit
Depreciation & Amortization	$10.00K	$2.000K
YoY Change
% of Gross Profit
Operating Expenses	$15.69M	$6.282M	$451.0K
YoY Change	3379.6%	2244.03%
Operating Profit	-$15.69M	-$6.282M	-$451.0K
YoY Change	3379.6%	2244.03%
Interest Expense	-$480.0K	$1.990M	-$10.00K
YoY Change	4700.0%	49650.0%
% of Operating Profit
Other Income/Expense, Net	-$82.31M	-$61.83M	-$33.00K
YoY Change	249333.33%	280945.45%
Pretax Income	-$98.01M	-$68.11M	-$480.0K
YoY Change	20318.75%	23386.21%
Income Tax
% Of Pretax Income
Net Earnings	-$98.01M	-$68.11M	-$484.0K
YoY Change	20149.17%	23386.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.869M	-$2.777M	-$18.55K
COMMON SHARES
Basic Shares Outstanding	24.53M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$243.8M	$74.50M
YoY Change
Cash & Equivalents	$243.8M	$74.48M	$879.0K
Short-Term Investments
Other Short-Term Assets	$11.80M	$3.200M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$255.6M	$77.65M	$902.0K
YoY Change	28237.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$463.0K	$40.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$181.0K	$2.013M
YoY Change
Total Long-Term Assets	$1.577M	$2.053M	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$255.6M	$77.65M	$902.0K
Total Long-Term Assets	$1.577M	$2.053M	$0.00
Total Assets	$257.2M	$79.71M	$902.0K
YoY Change	28411.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$699.0K	$439.0K	$55.00K
YoY Change	1170.91%
Accrued Expenses	$2.319M	$2.120M	$170.0K
YoY Change	1264.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$95.20M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.748M	$207.5M	$2.188M
YoY Change	71.3%
LONG-TERM LIABILITIES
Long-Term Debt	$22.78M	$22.60M
YoY Change
Other Long-Term Liabilities	$2.063M	$2.063M
YoY Change
Total Long-Term Liabilities	$24.84M	$2.063M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.748M	$207.5M	$2.188M
Total Long-Term Liabilities	$24.84M	$2.063M
Total Liabilities	$29.22M	$232.2M	$2.188M
YoY Change	1235.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$256.4M	-$158.4M	-$1.288M
YoY Change	19808.31%
Common Stock	$484.4M	$5.952M	$2.000K
YoY Change	24218600.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$228.0M	-$152.5M	-$1.286M
YoY Change
Total Liabilities & Shareholders Equity	$257.2M	$79.71M	$902.0K
YoY Change	28411.97%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$98.01M	-$68.11M	-$484.0K
YoY Change	20149.17%	23386.9%
Depreciation, Depletion And Amortization	$10.00K	$2.000K
YoY Change
Cash From Operating Activities	-$23.38M	-$7.110M	-$300.0K
YoY Change	7693.33%	2533.33%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$30.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$110.0K	-$20.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	192.8M	-1.290M	1.050M
YoY Change	18259.05%	-530.0%
NET CHANGE
Cash From Operating Activities	-23.38M	-7.110M	-300.0K
Cash From Investing Activities	-110.0K	-20.00K	0.000
Cash From Financing Activities	192.8M	-1.290M	1.050M
Net Change In Cash	169.3M	-8.420M	750.0K
YoY Change	22470.67%	-28166.67%
FREE CASH FLOW
Cash From Operating Activities	-$23.38M	-$7.110M	-$300.0K
Capital Expenditures	-$100.0K	-$30.00K
Free Cash Flow	-$23.28M	-$7.080M
YoY Change		2522.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1950000
CY2019Q3	phat	Warrant Liability Current WarrantLiabilityCurrent	107373000
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	207493000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2188000
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	22611000
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2013000
CY2019Q3	us-gaap	Assets Assets	79706000
CY2018Q4	us-gaap	Assets Assets	902000
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	439000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	55000
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2120000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	170000
CY2019Q3	us-gaap	Interest Payable Current InterestPayableCurrent	2332000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	13000
CY2019Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	95229000
	dei	Entity Central Index Key EntityCentralIndexKey	0001783183
	dei	Entity Registrant Name EntityRegistrantName	Phathom Pharmaceuticals, Inc.
	dei	Entity File Number EntityFileNumber	001-39094
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Trading Symbol TradingSymbol	PHAT
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60089
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	City Area Code CityAreaCode	(650)
CY2018Q4	us-gaap	Assets Current AssetsCurrent	902000
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40000
	dei	Entity Address City Or Town EntityAddressCityOrTown	Buffalo Grove
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24526537
	dei	Document Type DocumentType	10-Q
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-4151574
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2150 E. Lake Cook Road
	dei	Local Phone Number LocalPhoneNumber	325-5156
	us-gaap	Net Income Loss NetIncomeLoss	-157125000
	us-gaap	Net Income Loss NetIncomeLoss	-804000
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.30
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	879000
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3169000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23000
CY2019Q3	us-gaap	Assets Current AssetsCurrent	77653000
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74484000
	phat	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	207000
	phat	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0
CY2019Q3	phat	General And Administrative Expense Related Party GeneralAndAdministrativeExpenseRelatedParty	156000
CY2018Q3	phat	General And Administrative Expense Related Party GeneralAndAdministrativeExpenseRelatedParty	72000
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2063000
CY2019Q3	us-gaap	Liabilities Liabilities	232167000
CY2018Q4	us-gaap	Liabilities Liabilities	2188000
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5952000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2000
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158413000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1288000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-152461000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-1286000
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79706000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	902000
CY2019Q3	phat	Prepaid Expenses And Other Assets Related Parties Current PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent	36000
CY2018Q4	phat	Prepaid Expenses And Other Assets Related Parties Current PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent	19000
CY2019Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	57000
CY2018Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	45000
CY2019Q3	phat	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	176000
CY2018Q4	phat	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	2000
CY2019Q3	phat	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	483000
CY2018Q4	phat	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	13000
CY2019Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	21103000
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1950000
CY2019Q3	phat	Warrant Liabilities Related Parties Current WarrantLiabilitiesRelatedPartiesCurrent	106925000
CY2018Q4	phat	Warrant Liabilities Related Parties Current WarrantLiabilitiesRelatedPartiesCurrent	0
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11876518
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7420989
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4469000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7670000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6000
	phat	Process Research And Development ProcessResearchAndDevelopment	78897000
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1813000
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	262000
	us-gaap	Operating Expenses OperatingExpenses	90522000
	us-gaap	Operating Expenses OperatingExpenses	774000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6282000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-268000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-90522000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-774000
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	429000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	530000
CY2019Q3	us-gaap	Interest Expense InterestExpense	1990000
CY2018Q3	us-gaap	Interest Expense InterestExpense	4000
	us-gaap	Interest Expense InterestExpense	3138000
	us-gaap	Interest Expense InterestExpense	8000
CY2019Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	57776000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	59060000
CY2019Q3	phat	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-2486000
CY2018Q3	phat	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-18000
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7326090
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6760334
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6871471
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5812860
CY2019Q3	phat	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	207000
CY2018Q3	phat	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0
	phat	General And Administrative Expense Related Party GeneralAndAdministrativeExpenseRelatedParty	174000
	phat	General And Administrative Expense Related Party GeneralAndAdministrativeExpenseRelatedParty	196000
CY2019Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	302000
CY2018Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	4000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	498000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	8000
CY2019Q3	phat	Change In Fair Value Of Warrant Liabilities Related Party ChangeInFairValueOfWarrantLiabilitiesRelatedParty	57754000
CY2018Q3	phat	Change In Fair Value Of Warrant Liabilities Related Party ChangeInFairValueOfWarrantLiabilitiesRelatedParty	0
	phat	Change In Fair Value Of Warrant Liabilities Related Party ChangeInFairValueOfWarrantLiabilitiesRelatedParty	59031000
	phat	Change In Fair Value Of Warrant Liabilities Related Party ChangeInFairValueOfWarrantLiabilitiesRelatedParty	0
CY2019Q3	phat	Change In Fair Value Of Convertible Promissory Notes Related Party ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty	732000
CY2018Q3	phat	Change In Fair Value Of Convertible Promissory Notes Related Party ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty	18000
	phat	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-4928000
	phat	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-22000
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61830000
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-66603000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-68112000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-290000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-22.87
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	phat	Change In Fair Value Of Convertible Promissory Notes Related Party ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty	1053000
	phat	Change In Fair Value Of Convertible Promissory Notes Related Party ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty	22000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-1251000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-2537000
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5885000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-87762000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-84385000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	0
CY2018Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-254000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-252000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-260000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-512000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-802000
	us-gaap	Profit Loss ProfitLoss	-157125000
	us-gaap	Profit Loss ProfitLoss	-804000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2000
	us-gaap	Share Based Compensation ShareBasedCompensation	66000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	243000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	78897000
	phat	Fair Value Adjustment Of Convertible Promissory Notes FairValueAdjustmentOfConvertiblePromissoryNotes	4928000
	phat	Fair Value Adjustment Of Convertible Promissory Notes FairValueAdjustmentOfConvertiblePromissoryNotes	22000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3147000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	36000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1603000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	89000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2347000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	8000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	850000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1299000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	852000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	131000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	27000
	phat	Issuance Of Common Stock Warrants In Connection With Long Term Debt IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt	419000
	phat	Unpaid Initial Public Offering Costs UnpaidInitialPublicOfferingCosts	714000
	phat	Non Cash Final Interest Payment Fee NonCashFinalInterestPaymentFee	2063000
	phat	Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent	17000
	phat	Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent	8000
	phat	Increase Decrease In Accounts Payable And Accrued Expenses Related Parties IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties	186000
	phat	Increase Decrease In Accounts Payable And Accrued Expenses Related Parties IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties	32000
	phat	Increase Decrease In Interest Payable Related Parties IncreaseDecreaseInInterestPayableRelatedParties	483000
	phat	Increase Decrease In Interest Payable Related Parties IncreaseDecreaseInInterestPayableRelatedParties	13000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s combined financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s combined financial statements and accompanying notes. The most significant estimates in the Company’s combined financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	1,559.1183-for-1
CY2018	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1559.1183
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6760334
CY2019Q3	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q3	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2019Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2000000
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000
CY2019Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2389000
CY2019Q3	phat	Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear	458000
CY2019Q3	phat	Long Term Debt Maturities Repayments Of Principal And Interest In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo	1843000
CY2019Q3	phat	Long Term Debt Maturities Repayments Of Principal And Interest In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree	6609000
CY2019Q3	phat	Long Term Debt Maturities Repayments Of Principal And Interest In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour	9533000
CY2019Q3	phat	Long Term Debt Maturities Repayments Of Principal And Interest In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive	8920000
CY2019Q3	phat	Long Term Debt Maturities Repayments Of Principal And Interest In Year Six LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearSix	5599000
CY2019Q3	phat	Long Term Debt And Interest LongTermDebtAndInterest	32962000
CY2019Q3	phat	Debt Instrument Interest And Final Payment Fee DebtInstrumentInterestAndFinalPaymentFee	7962000
	phat	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Restrictions Placed On Previously Issued Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingRestrictionsPlacedOnPreviouslyIssuedShares	3373408
	phat	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Sale Of Unvested Common Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSaleOfUnvestedCommonStock	2524852
	phat	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issuance Of Unvested Restricted Stock Awards ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuanceOfUnvestedRestrictedStockAwards	16260
	phat	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting	1458985
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4455535
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1400528
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1400528
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.10
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.10
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3800000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y8M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6017
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0158
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0

Files In Submission

Name	View Source	Status
0001564590-19-044367-index-headers.html	Edgar Link	pending
0001564590-19-044367-index.html	Edgar Link	pending
0001564590-19-044367.txt	Edgar Link	pending
0001564590-19-044367-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
phat-10q_20190930.htm	Edgar Link	pending
phat-20190930.xml	Edgar Link	completed
phat-20190930.xsd	Edgar Link	pending
phat-20190930_cal.xml	Edgar Link	unprocessable
phat-20190930_def.xml	Edgar Link	unprocessable
phat-20190930_lab.xml	Edgar Link	unprocessable
phat-20190930_pre.xml	Edgar Link	unprocessable
phat-ex311_67.htm	Edgar Link	pending
phat-ex312_66.htm	Edgar Link	pending
phat-ex321_64.htm	Edgar Link	pending
phat-ex322_65.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHAT
Phathom Pharmaceuticals, Inc. Stock $phat

2019 Q4 Form 10-Q Financial Statement

#000156459019044367 Filed on November 25, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHAT Phathom Pharmaceuticals, Inc. Stock $phat

2019 Q4 Form 10-Q Financial Statement

#000156459019044367 Filed on November 25, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHAT
Phathom Pharmaceuticals, Inc. Stock $phat